Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ALXN1850 in treatment-naive children with hypophosphatasia
CTR20240840Phase 3Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of efzimfotase alfa in hypophosphatasia (HPP), sponsored by Alexion Pharmaceuticals. Started Aug 2024; status: active.
02
Drugs
efzimfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on CTR20240840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240840.